← 產業報告目錄
Neostigmine Methylsulfate Injection Market Size, Share & Trends Analysis Report By Application (Myasthenia Gravis, Reversal Of Neuromuscular Blockade), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User, By Region, And by Segment Forecasts, 2023-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-12頁數 175報告編號 INSIGHTACE-16c01e442a
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 156.54 Mn as of 2022, the global Neostigmine Methylsulfate Injection Market is projected to climb to USD 228.43 Mn by 2031, reflecting a compound annual growth rate of 4.4% over the 2023–2031 period.
Neostigmine Methylsulfate Injection covers a reversible cholinesterase inhibitor. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
The market's upward path is underpinned by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, underpinned by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neostigmine Methylsulfate Injection Market Snapshot
Chapter 4. Global Neostigmine Methylsulfate Injection Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Distribution Channel Estimates & Trend Analysis
5.1. By Distribution Channel, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Distribution Channel:
5.2.1. Hospital Pharmacies
5.2.2. Retail Pharmacies
5.2.3. Online Pharmacies
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. By Application & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Application:
6.2.1. Myasthenia Gravis
6.2.2. Reversal of Neuromuscular Blockade
Chapter 7. Market Segmentation 3: By End-use Estimates & Trend Analysis
7.1. By End-use & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End-use:
7.2.1. Hospitals
7.2.2. Specialty Clinics
7.2.3. Ambulatory Surgical Centers
Chapter 8. Neostigmine Methylsulfate Injection Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Neostigmine Methylsulfate Injection Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031
8.1.2. North America Neostigmine Methylsulfate Injection Market revenue (US$ Million) estimates and forecasts By Application, 2019-2031
8.1.3. North America Neostigmine Methylsulfate Injection Market revenue (US$ Million) estimates and forecasts By End-use, 2019-2031
8.1.4. North America Neostigmine Methylsulfate Injection Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Distribution Channel, 2019-2031
8.2.2. Europe Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Application, 2019-2031
8.2.3. Europe Neostigmine Methylsulfate Injection Market revenue (US$ Million) By End-use, 2019-2031
8.2.4. Europe Neostigmine Methylsulfate Injection Market revenue (US$ Million) by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Distribution Channel, 2019-2031
8.3.2. Asia Pacific Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Application, 2019-2031
8.3.3. Asia Pacific Neostigmine Methylsulfate Injection Market revenue (US$ Million) By End-use, 2019-2031
8.3.4. Asia Pacific Neostigmine Methylsulfate Injection Market revenue (US$ Million) by country, 2019-2031
8.4. Latin America
8.4.1. Latin America Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
8.4.2. Latin America Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
8.4.3. Latin America Neostigmine Methylsulfate Injection Market revenue (US$ Million) By End-use, (US$ Million) 2019-2031
8.4.4. Latin America Neostigmine Methylsulfate Injection Market revenue (US$ Million) by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
8.5.2. Middle East & Africa Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
8.5.3. Middle East & Africa Neostigmine Methylsulfate Injection Market revenue (US$ Million) By End-use, (US$ Million) 2019-2031
8.5.4. Middle East & Africa Neostigmine Methylsulfate Injection Market revenue (US$ Million) by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Pfizer Inc.
9.2.2. Fresenius Kabi AG
9.2.3. Mylan N.V.
9.2.4. Sandoz Inc
9.2.5. Bausch Health Companies Inc
9.2.6. Sun Pharmaceutical Industries Ltd
9.2.7. Hospira (now part of Pfizer)
9.2.8. Akorn Pharmaceuticals
9.2.9. Baxter International Inc.
9.2.10. Hikma Pharmaceuticals
9.2.11. Endo International
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們